People, every show

Bowen Liu

Investing Partner, Andreessen Horowitz. On 1 show, 1 appearance. The Shows tab opens the full record on each.

investorscientistengineera16z.com/bio-health ↗

Bowen Liu is an Investing Partner on the Bio + Health team at Andreessen Horowitz. He previously conducted machine learning and cheminformatics research at insitro and completed his Ph.D. at Stanford University.

What they said5 Shows1

Everything Bowen Liu said on any show that made the record, most notable first. Each card names its show and opens the statement there.

a16z Assertion Not checkable as stated

Liu: Protein structure prediction is essentially solved for many common proteins

“In the past, like, four or five years, this problem of protein structure prediction went from, you know, something that was, you know, quite far away from being solved, to now you could argue that, It's pretty much been solved for a lot of, like, common kind o…”

Bowen Liu Oct 3, 2024 ▶ 8:20 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

a16z Insight

Liu: Generative AI in science makes validation much harder than idea generation

“In science, you know, it's actually the inverse. Like, it's actually, it's probably easier to generate ideas, but way harder to validate.”

Bowen Liu Oct 3, 2024 ▶ 12:52 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

a16z Assertion Not checkable as stated

Bowen Liu calls labeled data scarcity the core bottleneck in scientific AI

“Yeah, I think you touched on, like, probably the core problem of, like, you know, ML applied to science. While we have a lot of, like, unlabeled data, like, there's just not that much label data out there. And a lot of it is because, like, it's very experiment…”

Bowen Liu Oct 3, 2024 ▶ 7:09 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

a16z Assertion Not checkable as stated

Bowen Liu: Small Molecules Currently Lack Self-Supervised Learning Frameworks

“Because like with protein sequences and biological sequences, like you can actually do self-supervised learning, right? Because there is this like complicated generative process with like evolutionary pressure that you can learn from. There's no equivalent for…”

Bowen Liu Oct 3, 2024 ▶ 18:05 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

a16z Assertion Not checkable as stated

Liu: 100 active compounds is a drug candidate but tiny for ML

“Usually in a drug discovery project, you know, if you have a hundred actives, you should be close to a drug, but a hundred data points is, like, tiny for machine learning, right?”

Bowen Liu Oct 3, 2024 ▶ 7:28 AI at the Intersection of Bio | Vijay Pande, Surya Ganguli & Bowen Liu

One line per show, most statements first. The link opens Bowen's full record on that show: the calibration, argument clarity, speaking style and every statement made there.

Show	Role there	Eps	Statements	Record
a16zLEDGER	Investing Partner, Andreessen Horowitz	1	5	—	full record on the a16z Podcast →